NCT03245554 is a EARLY_PHASE1 clinical trial of Propranolol in Gastrointestinal Cancer, sponsored by Central South University.

Who is sponsoring NCT03245554?

NCT03245554 is sponsored by Central South University.

What drugs are being tested in NCT03245554?

Interventions in NCT03245554: Propranolol.

What condition does NCT03245554 study?

NCT03245554 studies Gastrointestinal Cancer.

Is NCT03245554 still recruiting?

NCT03245554 is currently status unknown. Last updated 9 April 2018.

Last reviewed 2018-04-09 · How we verify

NCT03245554

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol

Status unknown EARLY_PHASE1 Last updated 9 April 2018

What this trial tests

EARLY_PHASE1 trial testing Propranolol in Gastrointestinal Cancer in 80 participants. Status unknown.

Timeline

1 May 2018

Primary endpoint
1 September 2020

1 September 2020

Quick facts

Lead sponsor	Central South University
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 May 2018
Primary completion	1 September 2020
Estimated completion	1 September 2020
Sites	1 location across China

Drugs / interventions tested

Propranolol (propranolol) — full drug profile →

Conditions studied

Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →

Sponsor

Central South University

Who can join

Adults 18 to 60, any sex, with Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To research the effect of propranolol on the proliferation and apoptosis of gastrointestinal cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, et al · · 2020 · cited 134× · PMID 33094495 · DOI 10.1002/ejhf.2029
Nerves in the Tumor Microenvironment: Origin and Effects.
Wang W, Li L, Chen N, Niu C, et al · · 2020 · cited 76× · PMID 33392191 · DOI 10.3389/fcell.2020.601738
Neuro-Mesenchymal Interaction Mediated by a β2-Adrenergic Nerve Growth Factor Feedforward Loop Promotes Colorectal Cancer Progression.
Kobayashi H, Iida T, Ochiai Y, Malagola E, et al · · 2025 · cited 42× · PMID 39137067 · DOI 10.1158/2159-8290.cd-24-0287
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.
Pu T, Sun J, Ren G, Li H. · · 2025 · cited 34× · PMID 40456735 · DOI 10.1038/s41392-025-02241-8
Trial watch: beta-blockers in cancer therapy.
Carnet Le Provost K, Kepp O, Kroemer G, Bezu L. · · 2023 · cited 25× · PMID 38126031 · DOI 10.1080/2162402x.2023.2284486
Sympathetic modulation of tumor necrosis factor alpha-induced nociception in the presence of oral squamous cell carcinoma.
Atherton MA, Park S, Horan NL, Nicholson S, et al · · 2023 · cited 16× · PMID 35714327 · DOI 10.1097/j.pain.0000000000002655
Clinical Use of Propranolol Reduces Biomarkers of Proliferation in Gastric Cancer.
Hu Q, Liao P, Li W, Hu J, et al · · 2021 · cited 10× · PMID 33981600 · DOI 10.3389/fonc.2021.628613
Neuroimmune crosstalk and its impact on cancer therapy and research.
Sharawy I. · · 2022 · cited 7× · PMID 35997976 · DOI 10.1007/s12672-022-00547-5

Verify or expand the search:

Other trials of Propranolol

Trials testing the same drug.

NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
NCT05741164 — Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory · Phase 2 · not yet recruiting
NCT07352228 — Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices · Phase 4 · enrolling by invitation
NCT07354126 — Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine · NA · recruiting
NCT06960850 — Effects of Oral Propranolol on Induction-Delivery Interval During Induction of Labour With Oxytocin · NA · not yet recruiting

Other recruiting trials for Gastrointestinal Cancer

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
NCT06936878 — BOLSTER: Learning New Skills to Thrive · NA · recruiting
NCT06864169 — A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) · Phase 2 · active not recruiting
NCT07056777 — Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastr · Phase 1, PHASE2 · recruiting

Other Central South University trials

Trials by the same sponsor.

NCT07444463 — Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications · NA · not yet recruiting
NCT07446478 — TIS for Improving Cognitive Impairment Associated With Schizophrenia · NA · not yet recruiting
NCT07045142 — Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients · Phase 3 · recruiting
NCT07066813 — Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces · recruiting
NCT07063901 — Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03245554 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central South University
Last refreshed: 9 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03245554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing